SALT LAKE CITY, UT--(Marketwire - January 31, 2013) - Q Therapeutics, Inc., an emerging biotechnology company developing innovative cell therapy products for the treatment of debilitating diseases of the central nervous system, today announced that the Company is scheduled to present at the 15th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 15th Annual BIO CEO & Investor Conference will take place February 11-12, 2013 at The Waldorf Astoria New York.
Now in its fifteenth year, the BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities.
EVENT AT A GLANCE
Deborah Eppstein, PhD - President and CEO
Steve Borst - CFO and Vice President, Corporate Development
Monday, February 11, 2013
3:30 PM ET
The Waldorf Astoria New York
301 Park Avenue
New York, New York
NOTE TO PRESS:
Qualified media are also invited to attend the event on a complimentary basis. Please visit www.bio.org/events/conferences/bio-ceo-media-registration or contact Tracy Cooley at 202-962-9200 or email@example.com to register for the event. To arrange one-on-one interviews with the executive management team of Q Therapeutics, please contact Erin Palmer at Hanover|Elite at 407-585-1080 or via email at QCEL@hanoverelite.com for scheduling details.
ABOUT THE BIO CEO & INVESTOR CONFERENCE
The 15th Annual BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. This year's conference will feature corporate presentations from more than 140 leading biotechnology and pharmaceutical companies, Fireside Chats with industry leaders, four Therapeutic Workshops and three Business Roundtables all drawing from seasoned industry executives and analysts. New this year, a special track of 25 high-caliber private companies will be presenting at the event, and plenary sessions will address timely business issues and industry trends. Attendees can expect many opportunities to schedule one-on-one meetings as well as numerous networking opportunities. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities.
About Q Therapeutics, Inc.
Headquartered in Salt Lake City, Utah, Q Therapeutics, Inc. is a fully reporting, non-trading company, engaged in developing adult stem cell therapies to treat debilitating diseases of the central nervous system. The Company's first product, Q-Cells®, is a cell-based therapeutic intended to restore or preserve normal activity of neurons by providing essential support functions that occur in healthy central nervous system tissues. Q-Cells may be applicable to a wide range of central nervous system diseases, including demyelinating conditions such as multiple sclerosis, transverse myelitis, cerebral palsy and stroke; as well as other neurodegenerative diseases and injuries, such as ALS (Lou Gehrig's disease), spinal cord injury, Parkinson's disease and Alzheimer's disease. Q Therapeutics' initial clinical target is ALS, with a first IND submission expected in 2013. For more information, visit www.qthera.com.